

PROVIDER ALERT

April 1, 2016



New Policy to Address Electric Tumor Treatment Fields

Alert

Medica will soon implement a new policy addressing the use of electric tumor treatment fields (ETTF) — e.g., Optune System — for the treatment of recurrent glioblastoma. ETTF is to be used as monotherapy in the treatment of histologically confirmed recurrent glioblastoma multiforme following chemotherapy, and it *will be eligible for coverage* if it meets certain criteria. For the treatment of newly diagnosed glioblastoma, ETTF *is considered investigative and therefore is not covered*.

This new utilization management (UM) policy for ETTF will be effective with June 1, 2016, dates of service, and prior authorization will be required. The policy will apply to all Medica products including government products unless a particular health plan (whether commercial, Medicare or Medicaid) requires different coverage.

Action

No action is required. The new UM policy will be available online as of June 1, 2016. [See Medica's UM policies](#) or call the Medica Provider Literature Request Line for a printed copy, toll-free at 1-800-458-5512, option 1, then option 5, ext. 2-2355.

[View previous Alerts](#) | [Contact Medica](#)



The address to the right is not for
mailing records or claims.